Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc. – Nasdaq
Nasdaq |
Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.
Nasdaq Chimeric antigen receptor T–cell (CAR-T) therapies and gene therapies are hot commodities these days. But some small biotechs developing CAR-T drugs and gene therapies are hotter than others. Over the last 12 months, bluebird bio (NASDAQ: BLUE) … |
